CureVac (CVAC) AI Stock Analysis

• Market Cap: $1.21B
• Dividend Yield: N/A
• Average Volume (3M): 427.55K
• Price to Earnings (P/E): 5.9
• Beta (1Y): 1.21
• Revenue Growth: 799.36%
• EPS Growth: N/A
• Country: US
• Employees: 825
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 225,172,740
• 10 Day Avg. Volume: 447,541
• 30 Day Avg. Volume: 427,548
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: 0.60
• Enterprise Value/Gross Profit: 0.63
• Enterprise Value/Ebitda: 1.28
• 1Y Price Target: $5.50
• Price Target Upside: 2.61% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: $6.00 ▲(11.94% Upside)

CureVac's strong financial performance and attractive valuation are the primary drivers of its stock score. The company's solid balance sheet and profitability metrics provide a stable foundation, while the low P/E ratio indicates potential undervaluation. Technical analysis suggests a neutral to slightly bullish trend, supporting the overall positive outlook.

Positive Factors

Strong Financial Position

A solid balance sheet with low debt-to-equity ratio and strong return on equity indicates financial stability, supporting long-term growth.

Cash Flow Generation

Improved free cash flow growth enhances the company's ability to invest in R&D and strategic initiatives, crucial for sustained innovation.

High Profit Margins

High profit margins reflect operational efficiency and strong pricing power, providing a buffer against market fluctuations.

Negative Factors

Declining Revenue Growth

A decline in revenue growth could indicate challenges in product adoption or market saturation, impacting future earnings potential.

Free Cash Flow Conversion

Lower conversion of net income to free cash flow may limit the company's ability to reinvest in growth opportunities and manage liabilities.

Revenue Growth Challenges

Challenges in sustaining revenue growth could hinder long-term expansion and market competitiveness, affecting overall business momentum.

CureVac Business Overview & Revenue Model

Company Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

How the Company Makes Money

CureVac makes money through the development and commercialization of its mRNA-based products. The company's revenue model is centered on the sale of its vaccines and therapeutics, which are developed in-house or in collaboration with strategic partners. Key revenue streams include licensing agreements, milestone payments, and royalties from commercialized products. Significant partnerships, such as those with pharmaceutical companies and research institutions, contribute to its earnings by providing additional funding, resources, and access to broader markets. These collaborations often involve joint development efforts, sharing of research data, and co-marketing of resultant products, which help CureVac expand its reach and accelerate product development.

CureVac Financial Statement Overview

Summary

CureVac demonstrates a strong financial position with impressive profitability metrics and a solid balance sheet. The company has effectively managed its debt levels and equity, resulting in high returns on equity. While revenue growth has faced challenges, the company has shown resilience in improving its cash flow generation.

Income Statement

CureVac's income statement shows a strong recovery with a TTM gross profit margin of 87.6% and a net profit margin of 34.5%. The EBIT and EBITDA margins are also robust at 39.9% and 43.5%, respectively. However, the revenue growth rate has declined by 2.5% in the TTM period, indicating potential challenges in sustaining revenue growth.

Balance Sheet

The balance sheet is solid with a low debt-to-equity ratio of 0.058, indicating low leverage. The return on equity is strong at 29.6%, reflecting efficient use of equity to generate profits. The equity ratio stands at 85.1%, showcasing a strong equity base relative to total assets.

Cash Flow

CureVac's cash flow statement highlights a significant improvement in free cash flow growth at 36.7% in the TTM period. The operating cash flow to net income ratio is healthy at 2.56, suggesting strong cash generation relative to net income. However, the free cash flow to net income ratio of 0.91 indicates that not all net income is translating into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	510.51M	535.18M	53.76M	67.42M	102.99M	48.90M
Gross Profit	484.00M	429.35M	-70.61M	-116.57M	-135.21M	34.73M
EBITDA	238.59M	209.69M	-234.09M	-209.39M	-386.49M	-123.09M
Net Income	193.64M	162.19M	-260.17M	-249.03M	-411.72M	-129.07M
Balance Sheet
Total Assets	688.88M	802.83M	788.25M	860.47M	1.16B	1.51B
Cash, Cash Equivalents and Short-Term Investments	395.81M	485.37M	405.11M	500.28M	816.11M	1.33B
Total Debt	36.03M	38.97M	41.82M	42.09M	28.89M	30.09M
Total Liabilities	102.51M	106.22M	271.31M	327.22M	469.77M	800.01M
Stockholders Equity	586.37M	696.61M	516.94M	533.25M	688.48M	711.35M
Cash Flow
Free Cash Flow	196.15M	83.41M	-323.09M	-379.40M	-861.03M	475.05M
Operating Cash Flow	204.08M	101.85M	-267.89M	-286.18M	-733.13M	522.40M
Investing Cash Flow	-7.93M	-18.44M	-55.20M	-93.50M	-127.90M	-45.27M
Financing Cash Flow	-5.39M	-5.11M	230.89M	63.17M	344.96M	819.83M

CureVac Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.36
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVAC, the sentiment is Neutral. The current price of 5.36 is below the 20-day moving average (MA) of 5.39, below the 50-day MA of 5.40, and above the 200-day MA of 4.37, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.59 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVAC.

CureVac Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	$1.21B	5.90	34.46%	―	799.36%	―
STOK	68 Neutral	$1.84B	39.68	18.17%	―	1218.82%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	48 Neutral	$1.23B	―	-113.22%	―	2133.71%	-15.38%
ABCL	46 Neutral	$1.67B	―	-15.64%	―	-0.54%	-6.28%
LENZ	46 Neutral	$1.09B	―	-26.25%	―	―	79.90%
ELVN	36 Underperform	$1.27B	―	-25.26%	―	―	-3.53%

CureVac Corporate Events

CureVac Reports Financial Losses in Mid-2025

CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline in revenue compared to the previous year. The company reported a net loss for the period, highlighting challenges in its financial performance. The financial results indicate a decrease in cash and cash equivalents, reflecting operational difficulties and potential impacts on stakeholders and market positioning.

CureVac Resolves Patent Litigation with Pfizer/BioNTech

On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of the settlement, CureVac and GSK will receive $740 million and royalties on U.S. vaccine sales. Additionally, CureVac will grant a non-exclusive license to BioNTech and Pfizer for mRNA-based products, which will expand globally upon BioNTech’s acquisition of CureVac. This resolution is expected to streamline CureVac’s operations and strengthen its industry position.